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Abstract
Background: Understanding the immune response to combination antiretroviral therapy (cART) is essential for a
clear approach to tuberculosis (TB) preventive therapy. We investigated the immunological recovery in cART-treated
HIV-infected patients developing TB compared to those who remained free of TB.
Methods: We extracted data of HIV-infected patients from a multicenter cohort for the HIV clinical surveillance in
Germany. No patients included in our study had TB at the beginning of the observation. Using a longitudinal mixed
model, we assessed the differences in the mean change of biomarkers (CD4+ cell count, CD8+ cell count, CD4:CD8
ratio and viral load) since cART initiation in patients who remained free of TB vs. those developing TB. To detect the
best-fit trajectories of the immunological biomarkers, we applied a multivariable fractional polynomials model.
Results: We analyzed a total of 10,671 HIV-infected patients including 139 patients who developed TB during follow-up.
The highest TB incidences were observed during the first two years since cART initiation (0.32 and 0.50 per 100 person-
years). In an adjusted multivariable mixed model, we found that the average change in CD4+ cell count recovery was
significantly greater by 33 cells/μl in patients who remained free of TB compared with those developing TB. After the
initial three months of cART, 65.6% of patients who remaining free of TB achieved CD4+ count of ≥400 cells/μl, while
only 11.3% of patients developing TB reached this immunological status after the three months of cART. We found no
differences in the average change of CD8+ cell count, CD4:CD8 ratio or viral load between the two-patient groups.
Conclusion: All HIV-infected patients responded to cART. However, patients developing TB showed reduced recovery in
CD4+ cell count and this might partly explain the incident TB in HIV-infected patients receiving cART. These findings
reinforce the importance of adjunctive TB preventive therapy for patients with reduced recovery in CD4+ cell count.
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Background
Infection with HIV is the most potent risk factor for tu-
berculosis (TB) [1]. HIV causes functional and numeric
depletion of TB-specific lymphocytes, leading to impair-
ment of both cell-mediated immune response, and granu-
loma formulation and maintenance [2]. Therefore,
co-infection with HIV increases the risk of progression to
active TB, and reactivation of latent TB infection (LTBI)
[3]. The introduction of combination antiretroviral ther-
apy (cART) in the mid-1990s has markedly reduced HIV-
related morbidity, and mortality [4]. Although cART is as-
sociated with a dramatic decline in TB risk by 70%-90%
among HIV-infected patients [5], TB incidence remains el-
evated in settings with high [5, 6] and low TB incidence
[5, 7]. Empirical observations and modelling studies sug-
gests that cART may have limited long-term impact on
TB incidence at a population level [8]. Also, HIV infection
was associated with lower TB treatment success rates even
in settings with available cART [9, 10].
TB preventive therapy can significantly reduce the risk
of TB among HIV-infected patients, even among those re-
ceiving cART, and living in areas with low TB rates
[11, 12]. Recently, TB preventive therapy for high-risk
groups including HIV-infected patients has attracted in-
creasing attention in developed countries, as WHO
launched a new action framework towards TB elimination
in low incidence countries [13]. It is recommended that
preventive therapy should be offered to HIV-positive pa-
tients particularly for those with positive tuberculin skin
tests (TST) [11, 12]. Such an approach has limitations due
to the low sensitivity of TST among HIV-infected patients
[14]. It has been observed that the proportion of TST-
positive results is associated with higher CD4+ cell count,
and TST-negative HIV-infected patients could still develop
active TB [15, 16]. The greater the immunosuppression, the
lower the probability of positive skin reaction [14, 17]. This
means that there is an increased risk that HIV-infected pa-
tients most in need will be left without preventive therapy.
Similarly, interferon-gamma release assays (IGRAs) have
clearly low sensitivity in HIV-positive patients and do not
offer any advantage over TST [18]. A multicenter European
study (TBNET Study) showed that progression towards ac-
tive TB in immunocompromised patients was poorly pre-
dicted by TST or IGRAs [19].
The majority of studies defined HIV-infected patients at
high risk for TB and, therefore, those who might benefit
from preventive therapy based on baseline CD4+ cell
count [6, 7, 20]. In addition to the lack of consensus on
the optimal threshold, this approach does not take into
account that TB risk changes over time in association with
ART-induced immune recovery. Despite the advances in
HIV literature on the immune response to cART, there is
still limited information on immune recovery in relation
to TB development. Investigating the growth dynamic of
immune biomarkers under cART is essential to under-
stand the risk of TB development in cART-treated pa-
tients and helps to improve our TB preventive therapy
approach.
In this study, we aimed to investigate whether the
average change in immunological biomarkers is associ-
ated with TB development and to analyze the immuno-
logical dynamic in cART-treated HIV-infected patients
in relation to development of active TB.
Methods
Data source and study population
The study was based on the German ClinSurv HIV Cohort,
which is an ongoing open multicentre cohort for the clin-
ical surveillance of HIV in Germany. The ClinSurv HIV co-
hort was established in 1999 as a collaborative cohort
between specialized treatment centres for HIV/AIDS and
the Robert Koch Institute. Irrespective of the disease stage,
all HIV-infected patients are eligible to attend one of the
treatment centres and can be enrolled in the ClinSurv HIV
Cohort. The ClinSurv dataset includes basic demographic
data recorded anonymously at the first contact. Clinical and
laboratory data are collected and updated in 3-month-
periods when data are available. The German ClinSurv HIV
Cohort has been described in detail elsewhere [7, 21].
For our analysis, we included patients who started cART
between 1999 and 2013. cART was defined as “triple-drug
therapy” involving two nucleoside reverse-transcriptase
inhibitors (NRTI) plus one non-nucleoside reverse-
transcriptase inhibitor (NNRTI) or protease inhibitor. We
excluded patients who developed TB during the first
3 months after cART initiation. These cases may reflect
unmasking active TB known as TB-associated immune re-
construction inflammatory syndrome (TB-IRIS) [22].
These cases are not clinically apparent prior to cART
initiation and manifest after the recovery of the immune
system induced by HIV therapy [22]. TB cases were de-
fined as any form of TB bacteriologically confirmed or
clinically diagnosed.
No patient included in our analysis has received TB
preventive therapy during follow-up observation. No
data were available on LTBI testing in the German
HIV Cohort.
Statistical analysis and modeling approach
Continuous variables were described using medians,
and interquartile ranges (IQR) and compared by a
nonparametric K-sample test on the equality of
medians. Categorical variables were described using
absolute and relative frequencies and compared by
the χ2 test for difference in proportion.
We used a Cox proportional hazards regression model
(survival analysis) to estimate the TB incidence rate de-
fined as the number of TB cases occurring per 100
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person-years of observation. The observation period was
calculated as the time from cART initiation to either
diagnosis of TB, last follow-up, a maximum of a 7-year
observation period (very few measurements were avail-
able beyond seven years of follow-up) or the last possible
observation date (30 June 2014).
We investigated the difference in the mean change
of each laboratory measurements (CD4+ cell count,
CD8+ cell count, CD4:CD8 ratio, and viral load) over-
time on cART between patients remained free of TB
vs. those developing TB. Laboratory measurements
were coded as time-varying variables and were the
main outcome variables. Subjects included in the
analysis required at least two serial measurements;
measurements taken after TB diagnosis were not in-
cluded in the analysis. Baseline measurements were
defined as the measurements taken at the date of
cART initiation. We fitted a separate longitudinal
mixed model for each laboratory biomarkers with
change since cART initiation at one year interval.
The purpose of this approach is to investigate the
pattern of the average change in biomarkers over time
on cART. We adjusted the models for sex, geograph-
ical origin, HIV transmission routes, age, year of
cART initiation and baseline value of biomarkers
(CD4+ cell count, CD8+ cell count, and viral load).
The models were corrected with a random intercept
and random slope to account for both individual dif-
ferences in the average change in immune recovery
and individual differences in trajectories across the
time of the study. A variance-covariance structure
was specified to account for the potential correlation
between repeated measurements for the same individ-
uals. Moreover, we added an interaction term between
TB and time on cART to compare the trajectory of
change between patients remained free of TB with
those developing TB.
To analyze the growth dynamics of the laboratory bio-
markers over time on cART, we used multivariable frac-
tional polynomials (MFP) to account for nonlinear
association and to detect the best-fit model [23]. The
MFP approach was adjusted for sex, geographical origin,
HIV transmission routes, age, year of cART initiation
and involves three steps: (1) test of covariates inclusion
by backward elimination at a p-value of <0.1, (2) test of
non-linearity at a p value of <0.05, (3) test of simplicity
of power transformation (first degree FP vs. second de-
gree FP) at a p-value of <0.05. Parameters in the final
model were estimated using the generalized estimating
equations (GEE) method. We used the GEE method to
account for possible correlation among the repeated
measurements taken in an individual and to deal with
longitudinal data on subjects with unequally spaced and
varying number of observations (accounting for missing
data). All analyses were performed using STATA
(version 14, StataCorp, LP, Texas, USA).
Results
Characteristics of the study population
From January 1999 through December 2013, a total of
11,293 HIV-infected patients initiated cART in the
German ClinSurv HIV Cohort. Patients known to have
TB prior to cART (N = 371), diagnosed with TB within
the initial 3 months of cART (N = 86), or with less than
two available serial laboratory measurements (165) were
excluded from our analysis. The majority of HIV-
infected patients remaining in our study (N = 10,671)
were male (77.4%), originated from Germany (69.8%),
and had a median age of 38 years at the time of cART
initiation. The baseline median CD4+ count was 285
cells/μl [IQR 172 – 413], the baseline median CD8+
count was 896 cells/μl [IQR 603 – 1301], the baseline
median CD4:CD8 ratio was 0.3 [IQR 0.2 – 0.5], and the
baseline viral load was 4.6 log10 copies/ml [IQR 3.6 –
5.2]. A total of 139 (1.3%) patients developed TB during
43,854 person-years follow-up (incidence of 0.32 per 100
person-years of follow-up; 95% confidence interval (CI)
0.27-0.37). Higher incidences were observed during the
first two years since cART initiation (1.2 and 0.5 per 100
person-years respectively) (Fig. 1). Differences in demo-
graphic and clinical characteristic between patients who
remained free of TB and those developing TB are pre-
sented in Table 1.
Trend of change in biomarkers since cART initiation in
relation to tuberculosis
In a mixed model with adjustment for sex, geographical
origin, HIV transmission routes, age, year of cART initi-
ation and baseline value of biomarkers (CD4+ cell count,
CD8+ cell count, and viral load), the recovery of bio-
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Fig. 1 Tuberculosis incidence among HIV-infected patients since cART
initiation in the German ClinSurv HIV cohort, 1999-2013. TB cases
diagnosed within the first three months of cART initiation were excluded.
cART: combination antiretroviral therapy
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count and CD4:CD8 ratio; decreasing in CD8+ cell
count and viral load) was significant for all investigated
biomarkers and irrespective to TB (Table 2) (Fig. 2).
However, patients remaining free of TB had significantly
a more marked increase in the change of CD4+ cell
count since cART initiation than those developing TB.
No significant difference in the pattern of change for
CD8+ cell count, CD4:CD8 ratio or viral load was ob-
served between the two-patient groups (Table 2) (Fig. 2).
Growth dynamics of CD4+, CD8+, CD4:CD8 ratio, and
viral load
After cART initiation, the general pattern of the CD4+ cell
count was increasing over time but at a decreasing rate.
Compared to patients remaining free of TB, patients de-
veloping TB showed less marked increase in CD4+ cell
count over time (P < 0.001) (Fig. 3a). After the initial
3 months of cART, 65.6% of patients who remaining
free of TB achieved CD4+ count of >400 cells/μl,
while just 11.3% of patients developing TB reached
this status within the same period (corresponding to
60% vs. 25% increase in CD4 cell counts compared to
the baseline values respectively). Similarly, the general
pattern of CD4:CD8 ratio improved substantially over
time; again patients who remained free of TB showed
faster recovery compared to patients developing TB
(P < 0.001) (Fig. 3c). After the initial phase, patients
remaining free of TB reached on average a 0.44
CD4:CD8 ratio, which was achieved by 56.1% of them
vs. 8.3% of patients developing TB.
In the initial 3 months of cART, CD8+ cell count
showed a sharp rise followed by a sharp decline
reaching approximately 1100 cell/μl after 3 months
of cART. Afterwards, CD8+ cell count decreased
slowly over time. No significant difference was
observed in the dynamics of CD8+ cell count in relation
to development of active TB (P = 0.48) (Fig. 2b). HIV viral
load showed a sharp drop in the initial phase of cART
Table 1 Characteristic of cART-treated HIV-infected patients in the German ClinSurv HIV Cohort, 1999-2013
Demographic and clinical characteristic of HIV
patients, N = 10,671 (100%)
HIV-infected patients who remained free of TB,
N = 10,532 (98.7%)
HIV-infected patients developing TB,
N = 139 (1.3%)
P value
Female sex 2388 (22.5%) 45 (31.5%) 0.01b
Age at time of cART initiation
Median (IQR), years 38.0 (31 – 45) 36.5 (31 – 45) 0.8c
Geographical origin
Germany 7289 (70.1%) 60 (42.9%) <0.001b
Sub-Saharan Africa 1344 (12.9%) 50 (35.7%)
South−/Southeast Asia 273 (2.7%) 10 (7.1%)
Others 1486 (14.3%) 20 (14.3%)
HIV-transmission routes
MSM 5377 (56.9%) 49 (36.6%) <0.001b
IDUs 886 (9.4%) 8 (6.0%)
Others 3186 (33.7%) 77 (57.4%)
Calendar year of cART initiation <0.001b
1999-2002 2524 (23.9%) 56 (24.2%)
2003-2008 4531 (43.1%) 58 (43.0%)
2009-2013 3477 (33.0%) 25 (32.8%)
Baseline CD4+ counta
Median (IQR), cells per μl 285 (173 – 413) 168 (80 - 326) 0.1c
Baseline CD8+ counta
Median (IQR), cells per μl 900 (602 – 1297) 846 (609 – 1364) 0.8c
Baseline CD4:CD8 ratioa
Median (IQR) 0.3 (0.2 – 0.5) 0.2 (0.1 – 0.3) 0.3c
Baseline viral loada
Median (IQR), log10 copies per ml 4.6 (3.6 – 5.2) 4.9 (3.7 – 5.1) 0.06
c
cART combination antiretroviral therapy, TB tuberculosis, IQR interquartile range, MSM men who have sex with men, IDU injecting drug users
aBaseline was defined as the measurements taken at the date of cART initiation
bObtained using a χ2 test for difference in proportion
cObtained using a non-parametric K-sample test on the equality of medians
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reaching approximately 2.5 log10 copies/ml followed
by a plateau (Fig. 3d). Patients who remained free of
TB had a plateau at a significantly lower level com-
pared to those developing TB (Fig. 3d). We applied
piecewise-linear trend models to assess the non-
linearity and patterns of change of biomarkers and it
confirmed our findings and showed no significant dif-
ferences from the trajectories obtained by the MPF
models (data not shown).
The trend of CD4+ cell count close to the time of
tuberculosis diagnosis
Using a fractional polynomial fit, we observed a decline
in CD4+ cell count around 5 months before TB diagno-
sis. However, this pattern in CD4+ cell count did not
show a significant drop since the fractional polynomial
growth does not fit the data significantly better than the
linear fit (deviance difference = 0.89; P = 0.8). In the lin-
ear regression model adjusted for sex, geographical ori-
gin, HIV-transmission routes, age, and year of cART
initiation, CD4+ cell count continued to recover over
time irrespective of the time of TB diagnosis [RC 0.07
CI 0.004 - 0.14, P = 0.04]. We could not investigate how
the trend of viral load, CD8+ cell count, and CD4:CD8
ratio developed at the time close to TB diagnosis as
there were insufficient measurements of these variables
around the time of TB diagnosis.
Discussion
We investigated the immunological recovery in cART-
treated HIV-infected patients in the German HIV cohort
in relation to development of active TB. Although patients
developing TB showed effective response to cART, we
found that the average change of increases in CD4+ count
was significantly smaller by 33 cells/μl compared with pa-
tients who remained free of TB. After the initial 3 months
of cART, 65.6% of patients who remaining free of TB
achieved CD4+ count of >400 cells/μl, while just 11.3% of
patients developing TB reached this status within the
Fig. 2 Change in biomarkers since cART initiation among HIV-infected patients in the ClinSurv HIV cohort, 1999-2013. (a) Change in CD4+ cell
count. (b) Change in CD8+ cell count. (c) Change in CD4:CD8 ratio. (d) Change in viral load
Table 2 Change in biomarkers since cART initiation among
HIV-infected patients in the ClinSurv HIV cohort, 1999-2013
Biomarkers Estimated change over time on cART (per year) P value
CD4+ count 43.9 cells per μl (95% CI 43.1 to 44.6) <0.001
CD8+ count −27.9 cells per μl (95% CI −28.6 to −27.2) <0.001
CD4:CD8 ratio 0.06 (95% 0.06 to 0.07) <0.001
Viral load −0.1 log10 copies per ml (95% CI −0.1 to −0.1) <0.001
Biomarkers Estimated mean of difference in change of
biomarkers between cART-treated patients
developing TB vs. those who remained free of
TB
P value
CD4+ count −33 cells per μl (95% CI −44.6 to 21.2) 0.001
CD8+ count −72 cells per μl (95% CI −84.6 to 1.7) 0.1
CD4:CD8 ratio −0.01 (95% CI −0.03 to 0.01) 0.2
Viral load 0.01 log10 copies per ml (−0.04 to 0 .06) 0.7
cART combination antiretroviral therapy, TB tuberculosis, IQR interquartile range
Longitudinal mixed models adjusted for sex, geographical origin, HIV transmission
routes, age, year of cART initiation and baseline value of biomarkers (CD4+ count,
CD8+ count, and viral load) and including interaction term between time and TB
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same period. We found no differences in the change of
CD8+ cell count, CD4:CD8 ratio or viral load between the
two-patient groups.
Excess TB rates during early cART were observed
in many studies and were attributed to cART-induced
unmasking of subclinical TB [7, 24]. However, we still
found a higher TB incidence in the first year of cART
in our study population, even after excluding cases
that occurred in the first 3 months of cART. The
mechanisms underlying development of TB in this
period are not fully understood and reflect a
spectrum of complex interactions between mycobac-
terial antigen load and cART-induced immune re-
sponse [22, 25–27]. Given the risk of subsequent
transmission due to unrecognized active TB and the
high disease burden of unmasked TB, all possible ef-
forts are needed to prevent it. Early initiation of
cART before significant immune depletion will poten-
tially decrease the risk of unmasking TB [26, 27].
In our data, patients developing TB started cART at
lower CD4+ cell count compared to patients remaining
free of TB. Despite not being statistically significant, this
lower baseline count may reflect a greater degree of pre--
treatment immunodeficiency, requiring for patients devel-
oping TB a more prolonged treatment period for CD4+
cell count to recover [28] and therefore could partially ex-
plain the reduced recovery among them. Different studies
done in high and low income countries showed that base-
line CD4+ cell count was independently associated with
higher risk of TB [6, 7, 20]. However, the increase of CD4
+ cell count remained significantly greater in patients who
remained free of TB after controlling for baseline bio-
markers. This different increase in CD4+ cell count might
partially explain the risk of TB in cART-treated HIV-
infected patients. These results are supported by findings
from a current study that showed that bacterial infections
in HIV-infected people was associated with change in CD
+ cell count since study entry [29]. Other studies showed
that baseline CD4+ cell count did not have any predictive
value for TB risk after controlling for the updated CD4+
cell count [30, 31].
The overall recovery of CD4+ cell count in the first
3 months of cART was relatively rapid, and then con-
tinued to rise at a slower rate. This is consistent with
other findings from HIV studies that show rapid in-
creases in CD4+ cell count among cART-treated patients
predominantly occur in the first months with comparatively
smaller gains thereafter [32–35]. Importantly, patients
developing TB lacked comparable immune recovery
and spent a substantial time at lower CD4+ cell count
and showed smaller increase in CD4+ count.
Therefore they remained at high TB risk for a long
period of time and this was mirrored by the higher TB in-
cidence occurring during this period. Immunological
studies suggest that full restoration of lymphocytes only
occurs in a minority of cART-treated patients and long-
term recovery of TB-specific immune function remains
incomplete despite continuous suppression of HIV repli-
cation [36, 37]. This hinders the extent to which cART
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Fig. 3 Immunological recovery since cART initiation among HIV-infected patients in the German ClinSurv HIV Cohort, 1999-2013. (a) Profile plot of CD4+ cell
count. (b) Profile plot of CD8+ cell count. (c) Profile plot of CD4:CD8 ratio. (d) Profile plot of viral load. The best-fitting model of CD4+ cells count is FP2
(0, 0.5) for subjects who remained free of TB and is FP2 (−1,1) for subjects who developed TB. Irrespective to TB development, the best-fitting model of
CD8+ cells count is FP2 (−0.5, −0.5)], of CD4:CD8 ratio is FP2 (−0.5, −0.5), and of viral load is FP2 (−2, −0.5). No measurements were included after TB
diagnosis. TB: tuberculosis; FP2: second-degree fractional polynomial model
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Isoniazid preventive therapy (IPT) is the most
widely used regimen and is strongly recommended by
WHO to decrease the burden of TB in HIV-infected
patients. TB preventive therapy can significantly re-
duce the risk of TB among HIV-infected patients,
even among those receiving cART, and living in areas
with low TB rates. However, implementation of IPT
at the same time as ART may be problematic due to
the difficulty in excluding active TB at baseline and
unmasking TB during the first months of ART.
Furthermore, inadequate patient adherence to IPT
and fear of promoting resistance to isoniazid through
IPT represent other major barriers to IPT implemen-
tation [38]. Different studies have suggested the use
of preventive therapy not only at baseline but also
serially or continuously for patients at higher risk of
TB [29, 39]. Our data add strong evidence to use im-
mune recovery to identify patients who could benefit
from adjunctive TB preventive therapy even if they
initially respond to cART. In light of our findings, a
logical approach might be to wait 3 months after
cART initiation in order to exclude unmasking TB
and then consider TB preventive therapy for patients
with reduced immune recovery. A prospective study
is required to confirm these findings and to identify a
threshold of CD4+ cell count blow which preventive
therapy should be considered in comparison to a
LTBI testing approach.
Similar to CD4+ cell count, CD4:CD8 ratio in patients
developing TB relatively recovered at a lower rate. Other
studies have shown that despite effective cART and CD4+
recovery above 500 cells/μl, a persistently low CD4:CD8
ratio acts as a marker of continuing immune dysfunction
[40], and the onset of HIV-related diseases [41]. However,
controlling for baseline biomarkers revealed no significant
difference in the average change of CD4:CD8 ratio over
time on cART.
We found that irrespective of TB progression, CD8+ cells
count increased markedly in the initial weeks of cART,
followed by a significant decrease and subsequent
plateau for the rest of follow-up. Elevation of CD8+
cell count occurs in the very early days of HIV infec-
tion as a general reaction to viral infections [42].
Sharp falls in CD8+ cell count can be observed
shortly after the initiation of cART but CD8+ cell
count remain persistently elevated during HIV infec-
tion and do not normalize despite long-term cART
[42, 43]. It is well-known that CD8+ cells play an
important role in the elimination of both TB- and
HIV-infected cells and consequent immune control.
Dysmature CD8+ cells are a common phenomenon in
HIV-infected patients; these CD8+ cells produce
significantly lower levels of perforin, granulysin, and
TNF-α which are crucial components of a protective
immune response to TB infection [42]. Again these
facts highlight the limitation of cART in TB preven-
tion in HIV-infected patients.
HIV viral load plateaued rapidly after a steep de-
cline in the initial 3 months of cART in both
patients developing TB and those who remained free
of TB. However, a higher level of viral load persisted
among patients developing TB compared to those
who remained free of TB. This might reflect the
differences in growth dynamic of CD4+ cell count
between them, where restoration of CD4+ cell count
is associated with the degree of suppression of HIV
replication.
Interestingly, our data showed a decline in CD4+ cell
count close to the time of TB diagnosis (around 5 months
prior). However, this finding was not statistically signifi-
cant and needs to be repeated with a larger sample size in
order to investigate the usefulness of a drop in CD4+ cell
count in predicting the onset of active TB. This hypothesis
is supported by the fact that depletion of CD4+ cell count
impairs cell-mediated immune responses, and granuloma
formation and function leading to an increased risk of ac-
tive TB [2].
There are some limitations to this study. Our ana-
lyses involved relatively few TB events (n = 139),
which might limits the study power. We could not
investigate the trend of CD8+ cell count, and viral
load close to TB diagnosis due to missing data. It is
unknown whether TB diagnosis was systematically
performed among all HIV-infected patients in the
ClinSurv HIV Cohort (active case finding) or whether
it was just a part of on-going health care (passive
case finding); therefore some TB cases may not have
been detected. The success rate of and adherence to
cART may play role in the immunological response
and it was not included in our analysis due to lack of
data. However, current study on the ClinSurv HIV
cohort showed that around 95% of the patients in the
cohort achieve viral suppression (viral load < 50 copies/ml),
suggesting a high success rate and adherence to cART
among patients [44].
Conclusion
Our findings highlight the strong association between TB
and the cART-induced response of CD4+ cell count in
HIV-infected patients. Although the initially response to
cART was observed, patients developing TB showed
reduced cART-induced increases in CD4+ cell count. This
might partly explain the incident TB in HIV-infected
patients receiving cART. These findings reinforce the
importance of adjunctive TB preventive therapy for those
patients with reduced recovery in CD4+ cell count.
Prospective studies are needed to confirm protective
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immunological thresholds for TB with an adequate assess-
ment of cART adherence.
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